Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18822243 | 1.00 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL20126461 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL21728798 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL19466410 | 0.92 | FURIN (0.44) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL21318749 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL25098213 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL20283603 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL19485764 | 0.92 | FURIN (0.44) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL22268356 | 0.91 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL24220965 | 0.91 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023448-A1 | DENDRIMER FOR THERAPY AND IMAGING | STARPHARMA PTY LTD. (AU) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023448-A1 | DENDRIMER FOR THERAPY AND IMAGING | PAICS, SLC7A1, SSTR3 | SIRT2 319/4885SIRT1 701/4885SIRT3 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.